Loading...
Docoh

Aptinyx (APTX)

Utility
Spiro-lactam and Bis-spiro-lactam Nmda Receptor Modulators and Uses Thereof
31 Mar 22
Disclosed are compounds having potency in the modulation of NMDA receptor activity.
M. Amin Khan
Filed: 7 May 21
Utility
Spiro-lactam Nmda Receptor Modulators and Uses Thereof
6 Jan 22
Disclosed are compounds having potency in the modulation of NMDA receptor activity.
M. Amin Khan
Filed: 17 Feb 21
Utility
Methods of Treating Cognitive Impairment Associated with Neurodegenerative Disease
21 Oct 21
Provided herein are methods of treating cognitive impairment associated with neurodegenerative disease in a patient by administering to the patient an effective amount of the Compound, or a pharmaceutically acceptable salt thereof.
Torsten M. Madsen, Ferenc Martenyi
Filed: 3 Dec 20
Utility
Spiro-lactam Nmda Receptor Modulators and Uses Thereof
21 Oct 21
Disclosed are compounds having potency in the modulation of NMDA receptor activity.
M. Amin Khan
Filed: 1 Dec 20
Utility
Methods of Treating Fibromyalgia
7 Oct 21
Provided herein are methods of treating fibromyalgia, in a patient by administering to the patient an effective amount of NYX-2925 or a pharmaceutically acceptable salt thereof.
Torsten M. Madsen
Filed: 10 Nov 20
Utility
Spiro-lactam NMDA receptor modulators and uses thereof
3 Aug 21
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity.
John A. Lowe, III, M. Amin Khan
Filed: 9 Aug 19
Utility
Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
8 Jun 21
Disclosed are compounds having potency in the modulation of NMDA receptor activity.
M. Amin Khan
Filed: 1 Aug 17
Utility
Spiro-lactam Nmda Receptor Modulators and Uses Thereof
27 May 21
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity.
John A. Lowe, III, M. Amin Khan
Filed: 2 Jul 20
Utility
Methods of Treating Painful Diabetic Peripheral Neuropathy
13 May 21
Provided herein are methods of treating painful diabetic peripheral neuropathy, such as advanced painful DPN, in a patient by administering to the patient an effective amount of NYX-2925 or a pharmaceutically acceptable salt thereof.
Torsten M. Madsen, M. Amin Khan, Mohsen Arghavani, Phil Bauer, Eduardo Mar
Filed: 10 Nov 20
Utility
Spiro-lactam NMDA receptor modulators and uses thereof
30 Mar 21
Disclosed are compounds having potency in the modulation of NMDA receptor activity.
M. Amin Khan
Filed: 1 Aug 17
Utility
Spiro-lactam Nmda Receptor Modulators and Uses Thereof
18 Feb 21
Disclosed are compounds having potency in the modulation of NMDA receptor activity.
M. Amin Khan
Filed: 31 Jan 19
Utility
Spiro-lactam NMDA receptor modulators and uses thereof
16 Feb 21
Disclosed are compounds having potency in the modulation of NMDA receptor activity.
M. Amin Khan
Filed: 1 Aug 17
Utility
Spiro-lactam Nmda Receptor Modulators and Uses Thereof
11 Feb 21
Disclosed are compounds having potency in the modulation of NMDA receptor activity.
M. Amin Khan
Filed: 31 Jan 19
Utility
Spiro-lactam Nmda Modulators and Methods of Using Same
6 Jan 21
Disclosed are compounds having potency in the modulation of NMDA receptor activity.
M. Amin Khan
Filed: 3 Feb 20
Utility
Spiro-lactam Nmda Receptor Modulators and Uses Thereof
1 Jul 20
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity.
John A. Lowe, III, M. Amin Khan
Filed: 8 Aug 19
Utility
Spiro-lactam and Bis-spiro-lactam Nmda Receptor Modulators and Uses Thereof
10 Jun 20
Disclosed are compounds having potency in the modulation of NMDA receptor activity.
M. Amin Khan
Filed: 31 Jul 17
Utility
Spiro-lactam Nmda Modulators and Methods of Using Same
30 Oct 19
Disclosed are compounds having potency in the modulation of NMDA receptor activity.
M. Amin Khan
Filed: 20 Nov 18
Utility
Spiro-lactam NMDA receptor modulators and uses thereof
14 Oct 19
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity.
John A. Lowe, III, M. Amin Khan
Filed: 1 May 18
Utility
Spiro-lactam NMDA receptor modulators and uses thereof
14 Oct 19
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity.
John A. Lowe, III, M. Amin Khan
Filed: 1 May 18
  • 1
Patents are sorted by USPTO publication date, most recent first